Andrew Cook, MD, on On-Going Clinical Research Efforts in the Head and Neck Cancer Space

Video

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss ongoing trials on treatment de-escalation and mitigating mucositis-related pain in head and neck cancer.

At the 2021 American Society for Radiation Oncology, CancerNetwork® spoke with Andrew Cook, MD, from Henry Ford Health System, about current ongoing trials in the head and neck cancer space, including efforts to better mitigate mucositis-related pain and treatment de-escalation.

Transcript:

At our specific institution, not myself, but some of my other colleagues are looking at an interesting question of what happens when you place an apparatus in a patient’s mouth to cool the oral mucosa while they’re undergoing radiation. [The intention is to] see if that may help to mitigate mucositis-related pain and improve quality of life going [for those] through treatments. That will be an exciting thing to see patients accrued on that and see what it may ultimately show. It’s an interesting idea. There are these other national trials looking at treatment deintensification of human papillomavirus positive oropharynx cancer, and those are going to be interesting. That's going to be a big direction of where the field is going.

Recent Videos
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.